2025-03-26 05:59:18
Latest Post
Rulka Electricals Secures 21 New Work Orders totaling Rs 12.36 Crore in March 2025
Ambo Agritec Ltd to expand presence in FMCG segment
Prism Johnson Ltd declared preferred bidder for mining lease of limestone block
Welspun Michigan Engineers Secures New Order to Upgrade the Haji Ali Storm Water Pumping Station in Mumbai
Capitalizing on Growth: Why Financial Services Firms Need a Unified AI Strategy
Stock Report
Bliss GVS Pharma Limited Q4 FY2023-24 consolidated loss at Rs. 9.14 crores
Posted On : 2024-05-04 12:02:47( TIMEZONE : IST )
Bliss GVS Pharma Limited has reported Consolidated financial results for the period ended March 31, 2024.
Financial Results (Q4 FY2024) - QoQ Comparison
The company has reported total income of Rs. 203.7278 crores during the period ended March 31, 2024 as compared to Rs. 206.1412 crores during the period ended December 31, 2023.
The company has posted net profit / (loss) of Rs. -9.1477 crores for the period ended March 31, 2024 as against net profit / (loss) of Rs. 27.6102 crores for the period ended December 31, 2023.
The company has reported EPS of Rs. -0.86 for the period ended March 31, 2024 as compared to Rs. 2.60 for the period ended December 31, 2023.
| Financials | Q4 FY2024 | Q3 FY2024 | % Change |
| Total Income | ₹ 203.7278 crs | ₹206.1412 crs |  -1.17% |
| Net Profit | ₹-9.1477 crs | ₹27.6102 crs | -133.13% |
| EPS | ₹-0.86 | ₹2.60 | -133.08% |
Financial Results (Q4 FY2024) - YoY Comparison
The company has reported total income of Rs. 203.7278 crores during the period ended March 31, 2024 as compared to Rs.187.7569 crores during the period ended March 31, 2023.
The company has posted net profit / (loss) of Rs.-9.1477 crores for the period ended March 31, 2024 as against net profit / (loss) of Rs.3.3438 crores for the period ended March 31, 2023.
The company has reported EPS of Rs.-0.86 for the period ended March 31, 2024 as compared to Rs.0.33 for the period ended March 31, 2023.
| Financials | Q4 FY2024 | Q4 FY2023 | % Change |
| Total Income | ₹ 203.7278 crs | ₹187.7569 crs |  8.51% |
| Net Profit | ₹-9.1477 crs | ₹3.3438 crs | -373.57% |
| EPS | ₹-0.86 | ₹0.33 | -360.61% |
Financial Results (Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.798.9823 crores during the Financial Year ended March 31, 2024 as compared to Rs.769.3739 crores during the Financial Year ended March 31, 2023.
The company has posted net profit / (loss) of Rs.75.4541 crores for the Financial Year ended March 31, 2024 as against net profit / (loss) of Rs.70.8588 crores for the Financial Year ended March 31, 2023.
The company has reported EPS of Rs.7.11 for the Financial Year ended March 31, 2024 as compared to Rs.6.72 for the Financial Year ended March 31, 2023.
| Financials | Year Ended FY2024 | Year Ended FY2023 | % Change |
| Total Income | ₹798.9823 crs | ₹769.3739 crs | 3.85% |
| Net Profit | ₹75.4541 crs | ₹70.8588 crs | 6.49% |
| EPS | ₹7.11 | ₹6.72 | 5.80% |
Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 119.10 as compared to the previous close of Rs. 129.20. The total number of shares traded during the day was 108457 in over 2150 trades.
The stock hit an intraday high of Rs. 122.00 and intraday low of 117.50. The net turnover during the day was Rs. 12973949.00.
